JP2022534069A5 - - Google Patents
Info
- Publication number
- JP2022534069A5 JP2022534069A5 JP2021569555A JP2021569555A JP2022534069A5 JP 2022534069 A5 JP2022534069 A5 JP 2022534069A5 JP 2021569555 A JP2021569555 A JP 2021569555A JP 2021569555 A JP2021569555 A JP 2021569555A JP 2022534069 A5 JP2022534069 A5 JP 2022534069A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide
- nucleotide sequence
- sequence
- sirna
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910441597 | 2019-05-24 | ||
| CN201910441597.6 | 2019-05-24 | ||
| PCT/CN2020/091606 WO2020238758A1 (zh) | 2019-05-24 | 2020-05-21 | 核酸、药物组合物与缀合物及制备方法和用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022534069A JP2022534069A (ja) | 2022-07-27 |
| JP2022534069A5 true JP2022534069A5 (enExample) | 2023-05-29 |
| JP7614650B2 JP7614650B2 (ja) | 2025-01-16 |
Family
ID=73553862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569555A Active JP7614650B2 (ja) | 2019-05-24 | 2020-05-21 | 核酸、薬物組成物及び複合体並びに調製方法と使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220315929A1 (enExample) |
| EP (1) | EP3992290A4 (enExample) |
| JP (1) | JP7614650B2 (enExample) |
| CN (1) | CN113891939B (enExample) |
| WO (1) | WO2020238758A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110944675B9 (zh) | 2017-12-01 | 2024-08-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| EP3719126B1 (en) | 2017-12-01 | 2025-01-01 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| EP3719127A4 (en) | 2017-12-01 | 2021-10-20 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| WO2020135673A1 (zh) | 2018-12-28 | 2020-07-02 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| AU2020280439B2 (en) | 2019-05-22 | 2025-08-14 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| US12590304B2 (en) | 2019-05-22 | 2026-03-31 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| KR20220011689A (ko) * | 2019-05-22 | 2022-01-28 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도 |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| EP4273245A4 (en) * | 2020-12-29 | 2024-12-11 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND SIRNA CONJUGATE WITH THE NUCLEIC ACID, MANUFACTURING PROCESS THEREOF AND USE THEREOF |
| US12042509B2 (en) | 2021-10-01 | 2024-07-23 | Adarx Pharmaceuticals, Inc. | Prekallikrein-modulating compositions and methods of use thereof |
| TW202346586A (zh) * | 2022-01-28 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 用於抑制前激肽釋放酶（pkk）蛋白表達的組合物和方法 |
| CN120209051A (zh) * | 2023-12-27 | 2025-06-27 | 武汉人福创新药物研发中心有限公司 | 用于递送的靶向化合物及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| WO2005116204A1 (ja) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Ｒｎａ干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| CN103380113B (zh) | 2010-11-15 | 2018-03-30 | 生命科技公司 | 含胺的转染试剂及其制备和使用方法 |
| KR102320178B1 (ko) * | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| AU2013299717B2 (en) | 2012-08-06 | 2018-06-28 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugated RNA agents and process for their preparation |
| DK2992098T3 (da) | 2013-05-01 | 2019-06-17 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression |
| WO2015006740A2 (en) | 2013-07-11 | 2015-01-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
| KR102365486B1 (ko) * | 2013-08-28 | 2022-02-18 | 아이오니스 파마수티컬즈, 인코포레이티드 | 프리칼리크레인 (pkk) 발현의 조절 |
| EA038532B1 (ru) * | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
| HUE052709T2 (hu) * | 2014-05-01 | 2021-05-28 | Ionis Pharmaceuticals Inc | Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására |
| IL316808A (en) * | 2014-08-20 | 2025-01-01 | Alnylam Pharmaceuticals Inc | Modified double-stranded RNA materials and their uses |
| JP6695902B2 (ja) | 2015-05-06 | 2020-05-20 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
-
2020
- 2020-05-21 US US17/595,576 patent/US20220315929A1/en not_active Abandoned
- 2020-05-21 CN CN202080037247.4A patent/CN113891939B/zh active Active
- 2020-05-21 EP EP20815633.1A patent/EP3992290A4/en not_active Withdrawn
- 2020-05-21 JP JP2021569555A patent/JP7614650B2/ja active Active
- 2020-05-21 WO PCT/CN2020/091606 patent/WO2020238758A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022534069A5 (enExample) | ||
| JP2022533722A5 (enExample) | ||
| JP2022534702A5 (enExample) | ||
| JP2022533841A5 (enExample) | ||
| JP2021503941A5 (enExample) | ||
| JP2021503940A5 (enExample) | ||
| JP2022535708A5 (enExample) | ||
| JP2022533421A5 (enExample) | ||
| JP2022533419A5 (enExample) | ||
| JP2021503929A5 (enExample) | ||
| JP2021533800A5 (enExample) | ||
| JP2021503930A5 (enExample) | ||
| JP2022501059A5 (enExample) | ||
| JP2022535911A5 (enExample) | ||
| JP7249080B2 (ja) | 可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用 | |
| JP2023536320A5 (enExample) | ||
| HRP20250277T1 (hr) | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba | |
| ES2924806T3 (es) | Análogos de 4'-fosfato y oligonucleótidos que comprenden el mismo | |
| CA2879066C (en) | Chiral nucleic acid adjuvant | |
| JP2022528840A5 (enExample) | ||
| JP2025165976A5 (enExample) | ||
| JP7748500B2 (ja) | トリループを含む二本鎖核酸インヒビター分子 | |
| JP2010538677A5 (enExample) | ||
| HRP20250408T1 (hr) | Kojugati i njihova priprema i uporaba | |
| JP2019530656A5 (enExample) |